"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
MeSH Number(s)
E02.095.465.425.400.330.050.400
E05.478.550.520.050.400
Concept/Terms
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in Harvard Catalyst Profiles by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 6 | 10 | 16 |
| 1994 | 6 | 5 | 11 |
| 1995 | 4 | 4 | 8 |
| 1996 | 4 | 6 | 10 |
| 1997 | 2 | 3 | 5 |
| 1998 | 3 | 2 | 5 |
| 1999 | 2 | 5 | 7 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 3 | 6 |
| 2003 | 3 | 6 | 9 |
| 2004 | 4 | 0 | 4 |
| 2005 | 4 | 2 | 6 |
| 2006 | 2 | 4 | 6 |
| 2007 | 5 | 1 | 6 |
| 2008 | 6 | 5 | 11 |
| 2009 | 2 | 3 | 5 |
| 2010 | 2 | 3 | 5 |
| 2011 | 10 | 0 | 10 |
| 2012 | 3 | 8 | 11 |
| 2013 | 6 | 4 | 10 |
| 2014 | 8 | 6 | 14 |
| 2015 | 10 | 5 | 15 |
| 2016 | 10 | 5 | 15 |
| 2017 | 20 | 5 | 25 |
| 2018 | 36 | 10 | 46 |
| 2019 | 42 | 11 | 53 |
| 2020 | 47 | 23 | 70 |
| 2021 | 45 | 27 | 72 |
| 2022 | 15 | 52 | 67 |
| 2023 | 9 | 46 | 55 |
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023 Nov 14; 7(21):6599-6603.
-
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 2023 11 01; 108(11):2972-2981.
-
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 11; 21(11):1118-1131.
-
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity. 2023 10 10; 56(10):2296-2310.
-
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood. 2023 10 05; 142(14):1248-1252.
-
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576.
-
Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023 09 26; 7(18):5485-5495.
-
In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma. Theranostics. 2023; 13(15):5170-5182.
-
Engineering CAR T Cells for Off-the-Shelf Use. N Engl J Med. 2023 Sep 07; 389(10):953-957.
-
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood Cancer Discov. 2023 09 01; 4(5):365-373.